Page last updated: 2024-11-04

mefenamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain and reduce fever. It is available over-the-counter and by prescription. Mefenamic acid is thought to work by blocking the production of certain natural substances that cause pain, swelling, and fever. The synthesis of mefenamic acid involves multiple steps, starting with the reaction of 2-chloro-4-nitrobenzoic acid with 2-amino-4-methylphenol. This reaction is followed by a series of steps, including reduction, alkylation, and hydrolysis, to yield the final product. Mefenamic acid is a potent anti-inflammatory agent that has been shown to be effective in the treatment of a variety of conditions, including pain associated with osteoarthritis, rheumatoid arthritis, and dysmenorrhea. It is also used to reduce fever and to treat mild to moderate pain. The mechanism of action of mefenamic acid is thought to be related to its ability to inhibit the production of prostaglandins, which are hormones that play a role in inflammation and pain. However, mefenamic acid has also been shown to have other effects, such as reducing platelet aggregation, which may contribute to its anti-inflammatory properties. Mefenamic acid has been studied extensively for its potential therapeutic benefits in a variety of conditions, including inflammatory bowel disease, cancer, and HIV infection. It is also being investigated for its potential use in the treatment of Alzheimer's disease and Parkinson's disease. Research on mefenamic acid is ongoing, and it is likely that new uses for this drug will be discovered in the future. '

Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4044
CHEMBL ID686
CHEBI ID6717
SCHEMBL ID3544
MeSH IDM0013283

Synonyms (229)

Synonym
namphen
cn 35355
mycasaal
rolan
ponstan forte
anthranilic acid, n-(2,3-xylyl)-
2-((2,3-dimethylphenyl)amino)benzoic acid
acidum mefenamicum [inn-latin]
mefenaminsaeure [german]
hsdb 3115
acide mefenamique [inn-french]
mefenaminic acid
nsc 94437
ac. mefenamico [italian]
benzoic acid, 2-(2,3-dimethylphenyl)amino-
bafhameritin-m
anthranilic acid, n-2,3-xylyl-
brn 2216243
benzoic acid, 2-((2,3-dimethylphenyl)amino)-
acide mefenamique [french]
mefedolo
acido mefenamico [inn-spanish]
einecs 200-513-1
2-diphenylaminecarboxylic acid, 2',3'-dimethyl-
MLS001074162
AKOS002388313
AB00052200-17
brd-8217
BRD-K92778217-001-06-1
brd8217
bafameritin-m
mefacit
inf 3355
tamany bonsan
coslan
ponstan
benzoic acid, 2-[(2,3-dimethylphenyl)amino]-
n-(2,3-xylyl)anthranilic acid
mephenamic acid
agn-1255
bonabol
cl 473
lysalgo
ponstel
ponstyl
mephenaminic acid
parkemed
2-(2,3-dimethylanilino)benzoic acid
methenamic acid
hl 1
ponalar
tanston
nsc94437
ci-473 ,
inf-3355
pontal
n-2,3-xylylanthranilic acid
cn-35355
ponstil
vialidon
ci 473
DIVK1C_000298
KBIO1_000298
SGCUT00005
D00151
mefenamic acid (jp17/usp/inn)
SPECTRUM_000174
BPBIO1_000229
SPECTRUM5_001341
PRESTWICK2_000054
PRESTWICK_506
cas-61-68-7
NCGC00016278-01
UNM000001233403
SMP2_000141
BSPBIO_000207
nsc-94437
n-(2,3-xylyl)-2-aminobenzoic acid
n-(2,3-dimethylphenyl)anthranilic acid
2-diphenylaminecarboxylic acid,3'-dimethyl-
wln: qvr bmr b1 c1
benzoic acid,3-dimethylphenyl)amino]-
anthranilic acid,3-xylyl-
OPREA1_193889
PRESTWICK3_000054
inchi=1/c15h15no2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16h,1-2h3,(h,17,18
2-[(2,3-dimethylphenyl)amino]benzoic acid
AB00052200
61-68-7
mefenamic acid
C02168
TO_000071
DB00784
IDI1_000298
NCGC00022393-03
NCGC00022393-05
NCGC00022393-04
MLS000069709 ,
smr000058188
KBIO2_005790
KBIO2_003222
KBIOGR_001730
KBIOSS_000654
KBIO3_001944
KBIO2_000654
SPBIO_002001
PRESTWICK0_000054
SPECTRUM3_001082
NINDS_000298
SPECTRUM4_001235
SPECTRUM2_001941
PRESTWICK1_000054
SPBIO_002128
SPECTRUM1501103
BSPBIO_002724
NCGC00016278-02
gtpl2593
AC-11160
HMS2090B07
HMS2092B17
2-(2,3-xylidino)benzoic acid
m1782 ,
2-(2,3-dimethylphenylamino)benzoic acid
cid_4044
bdbm50134036
mefanamic acid
2-(2,3-dimethyl-phenylamino)-benzoic acid
2-(2,3-dimethyl-phenylamino)-benzoic acid(mefenamic acid)
mefenamate
CHEMBL686 ,
j2.344b ,
m01ag01
chebi:6717 ,
gardan
HMS500O20
HMS1921D13
HMS1568K09
STK666691
AKOS001025551
cpd000058188
NCGC00016278-07
2-(2,3-dimethylanilino)benzoic acid;mefenamic acid
A833367
HMS2095K09
HMS3259M19
BBL003564
dtxcid103243
NCGC00255401-01
tox21_301983
dtxsid5023243 ,
nsc-757834
pharmakon1600-01501103
nsc757834
tox21_110344
HMS2232P18
S4078
CCG-39434
NCGC00016278-06
NCGC00016278-03
NCGC00016278-04
NCGC00016278-05
in-m
mefenacid
acidum mefenamicum
acido mefenamico
367589pj2c ,
mefenamic acid [usan:usp:inn:ban:jan]
mefenaminsaeure
acide mefenamique
unii-367589pj2c
ac. mefenamico
FT-0628184
AM20060688
mefenamic acid [inn]
mefenamic acid [vandf]
mefenamic acid [usp-rs]
mefenamic acid [who-dd]
mefenamic acid [ep monograph]
mefenamic acid [mart.]
mefenamic acid [usan]
2-(2,3-dimethylphenyl)aminobenzoic acid
mefenamic acid [mi]
mefenamic acid [jan]
mefenamic acid [hsdb]
mefenamic acid [usp monograph]
mefenamic acid [orange book]
F0850-6853 ,
HMS3370K18
HY-B0574
NC00517
SCHEMBL3544
NCGC00016278-10
tox21_110344_1
2-[(2,3-dimethylphenyl) amino]benzoic acid
W-105113
2-(2,3-dimethylanilino)benzoic acid #
AB00052200_18
OPERA_ID_542
AB00052200_19
mfcd00051721
mefenamic acid, analytical standard
sr-01000000216
SR-01000000216-2
mefenamic acid, united states pharmacopeia (usp) reference standard
HMS3652A10
mefenamic acid, european pharmacopoeia (ep) reference standard
SR-01000000216-4
Z56755828
SBI-0051636.P002
HMS3712K09
SW196700-3
BCP08499
Q284321
mefenamic acid,(s)
AS-12677
EN300-16695
HMS3885O22
mefenamic-acid
SY045797
mefenamic acid (usp monograph)
mefenamic acid (usan:usp:inn:ban:jan)
mefenamic acid (ep monograph)
acido mefenamico (inn-spanish)
benzoic acid, 2-((2,3-dimethyl(phenyl)amino)-
mefenamic acid (mart.)
mefenaminsaure
mefenamic acid (usp-rs)
acide mefenamique (inn-french)
acidum mefenamicum (inn-latin)

Research Excerpts

Overview

Mefenamic acid is a non-steroidal anti-inflammatory drug able to control the symptoms of osteoarthritis. Its effects on protection of cartilage and bone are still unclear. Mefenamic acid (MFA) is a poorly soluble drug thought to limit the dissolution rate for membrane permeation.

ExcerptReferenceRelevance
"Mefenamic acid is a non‑steroidal anti‑inflammatory drug exhibiting a wide range of anti‑inflammatory, antipyretic, analgesic and probable antiviral activities. "( Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID‑19: A randomized double‑blind placebo‑controlled trial.
Beas-Guzman, O; Cardenas-Aguilar, CB; Chaviano-Conesa, D; Cuevas-Velazquez, AC; Delgado-Enciso, I; Delgado-Enciso, J; Delgado-Enciso, OG; Galvan-Salazar, HR; Garcia-Garcia, HS; Guzman-Esquivel, J; Guzman-Solorzano, HP; Guzman-Solorzano, JA; Martinez-Fierro, ML; Melnikov, V; Mokay-Ramirez, KA; Murillo-Zamora, E; Paz-Michel, BA; Rodriguez-Sanchez, IP; Rojas-Larios, F; Walle-Guillen, M, 2022
)
2.47
"Mefenamic acid is a non-steroidal anti-inflammatory drug able to control the symptoms of osteoarthritis (OA), but its effects on protection of cartilage and bone are still unclear. "( Mefenamic acid decreases inflammation but not joint lesions in experimental osteoarthritis.
Aguiar, GC; Amaral, FA; Caliari, MV; Ferreira, AJ; Queiroz-Junior, CM; Sitta, GL; Teixeira, MM, 2016
)
3.32
"Mefenamic Acid (MFA) is a widely-used non-steroidal anti-inflammatory drug. "( Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance.
Antonio, M; Maggio, RM, 2018
)
2.28
"Mefenamic acid is a fenamate nonsteroidal anti-inflammatory (NSAI) drug, which is used for several years for pain management. "( Central nervous system toxicity due to mefenamic acid.
Çaylak, ST; Doğan, NÖ; Yılmaz, S, 2019
)
2.23
"Mefenamic acid (MFA) is a poorly soluble drug thought to limit the dissolution rate for membrane permeation."( In-situ dissolution and permeation studies of nanocrystal formulations with second-derivative UV spectroscopy.
Imono, M; Kadota, K; Tozuka, Y; Uchiyama, H; Ueda, H, 2019
)
1.24
"Mefenamic acid (MA) is a BCS II class NSAID drug. "( Nano-proniosomes enhancing the transdermal delivery of mefenamic acid.
Farid, RM; Kassem, AA; Wen, MM, 2014
)
2.09
"Mefenamic acid (MEF) is a widely prescribed non-steroidal anti-inflammatory drug that has been found associated with rare but severe cases of hepatotoxicity, nephrotoxicity and gastrointestinal toxicity. "( Identification and disposition of novel mono-hydroxyl mefenamic acid and their potentially toxic 1-O-acyl-glucuronides in vivo.
Fong, SY; Han, Q; Wong, YC; Zhang, Y; Zhou, L; Zuo, Z, 2015
)
2.11
"Mefenamic acid (MA) is a widely used non-steroidal antiinflammatory (NSAID) drug. "( Preparation and investigation of mefenamic acid - polyethylene glycol - sucrose ester solid dispersions.
Aigner, Z; Croitoru, MD; Deli, MA; Fülöp, I; Gyéresi, Á; Kiss, L; Szabó-Révész, P, 2015
)
2.14
"Mefenamic acid (MEF) is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate pain, and for the treatment of primary dysmenorrhea. "( Removal of Mefenamic acid from aqueous solutions by oxidative process: Optimization through experimental design and HPLC/UV analysis.
Colombo, R; Ferreira, RA; Ferreira, TC; Lanza, MR, 2016
)
2.27
"Mefenamic acid is a well-known NSAID and is used in the treatment of musculoskeletal disorders, inflammation, fever, and pain."( Immunomodulatory activity of mefenamic acid in mice models of cell-mediated and humoral immunity.
Arshad, HM; Ashraf, MI; Shabbir, A; Shahzad, M; Shamsi, S,
)
1.14
"Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID). "( Single dose oral mefenamic acid for acute postoperative pain in adults.
Derry, S; McQuay, HJ; Moll, R; Moore, RA, 2011
)
2.15
"Mefenamic acid is a common widely prescribed drug with analgesic activity. "( 'Dalmatian dog'-like skin eruption (two cases of multifocal fixed drug eruption induced by mefenamic acid).
Anyfantakis, V; Christophidou, E; Kalogirou, O; Katsambas, A; Papadakis, P; Rallis, E; Rigopoulos, D, 2005
)
1.99
"Mefenamic acid is an analgesic, antipyretic and anti-inflammatory agent. "( The effects of mefenamic acid on hematocrit of the lizard, Uromastix hardwickii.
Ahmad, M; Ahmed, M; Ahmed, Z; Hasan, R; Qureshi, A, 2006
)
2.13
"Mefenamic acid is a nonsteroidal anti-inflammatory drug commonly used in analgesia. "( Reactivity of mefenamic acid 1-o-acyl glucuronide with proteins in vitro and ex vivo.
Burchell, B; Hosagrahara, VP; McGurk, KA; Remmel, RP; Tosh, D, 1996
)
2.1
"Mefenamic acid is a relatively potent and selective inhibitor of HL-PST."( Fenamates and the potent inhibition of human liver phenol sulphotransferase.
De Santi, C; Mosca, F; Pacifici, GM; Pietrabissa, A; Vietri, M, 2000
)
1.03
"Mefenamic acid is a problematic drug in granulation, tableting, and dissolution due to its poor solubility, hydrophobicity, and tendency to stick to surfaces. "( Some physicochemical properties of mefenamic acid.
Adam, A; Schmidt, PC; Schrimpl, L, 2000
)
2.03
"Mefenamic acid (MA) is a nonsteroidal anti-inflammatory drug used as analgesic and antipyretic drug. "( Preparation of mefenamic acid sustained release beads based on kappa-carrageenan.
Bergişadi, N; Ozsoy, Y,
)
1.93
"Mefenamic acid (MA) is a nonsteroidal antiinflammatory analgesic agent widely used clinically. "( Rapid and sensitive liquid chromatographic assay of mefenamic acid in plasma.
Cheymol, G; Lebot, M; Poirier, JM, 1992
)
1.98
"Mefenamic acid proved to be a potent and efficacious agent in the control of unexplained menorrhagia."( Management of cyclical menorrhagia with prostaglandin synthetase inhibitor.
Grover, V; Gupta, U; Kalra, S; Usha, R, 1990
)
1

Effects

Mefenamic acid (MFA) has been associated with rare but severe cases of hepatotoxicity, nephrotoxicity, gastrointestinal toxicity, and hypersensitivity reactions that are believed to result from the formation of reactive metabolites. It has analgesic, anti-inflammatory and antipyretic properties.

ExcerptReferenceRelevance
"Mefenamic acid (MFA) has been associated with rare but severe cases of hepatotoxicity, nephrotoxicity, gastrointestinal toxicity, and hypersensitivity reactions that are believed to result from the formation of reactive metabolites. "( Cytochrome P450-mediated bioactivation of mefenamic acid to quinoneimine intermediates and inactivation by human glutathione S-transferases.
Commandeur, JN; den Braver, MW; Venkataraman, H; Vermeulen, NP, 2014
)
2.11
"Mefenamic acid (MA) has analgesic, anti-inflammatory and antipyretic properties. "( Investigations on mefenamic acid sustained release tablets with water-insoluble gel.
Araman, A; Cevher, E; Güngör, S; Ozsoy, Y; Yildiz, A, 2003
)
2.1
"Mefenamic acid (MFA) has anti-convulsant and pro-convulsant effects in vivo, and has been shown to potentiate and inhibit GABAA (gamma-aminobutyric acid) receptors in vitro. "( Subunit-selective modulation of GABAA receptors by the non-steroidal anti-inflammatory agent, mefenamic acid.
Halliwell, RF; James, CH; Martinez-Torres, A; Miledi, R; Patten, D; Smart, TG; Thomas, P, 1999
)
1.97

Actions

ExcerptReferenceRelevance
"Mefenamic acid appears to increase survival rates especially when crushing is performed after 31 days, although the twin of apparently successful crushings at this stage may be lost between Days 50 and 70."( Termination of twin gestation by blastocyst crush in the broodmare.
Roberts, CJ, 1982
)
0.99

Treatment

Mefenamic acid (MFA) treatment is associated with a number of cellular effects that potentiate the incidence of renal toxicity. Treatment with mefenamic acid resulted in less volume of blood loss compared to tranexamic acid.

ExcerptReferenceRelevance
"Mefenamic acid (MFA) treatment is associated with a number of cellular effects that potentiate the incidence of renal toxicity. "( Renal ultrastructural alterations induced by various preparations of mefenamic acid.
Cheema, MS; Hakim, MN; Jarrar, QB; Moshawih, S; Zakaria, ZA, 2020
)
2.24
"Mefenamic acid treated groups showed a significant reduction in antibody titer against sheep RBCs as compared to control group, similar to the effect of cyclophosphamide."( Immunomodulatory activity of mefenamic acid in mice models of cell-mediated and humoral immunity.
Arshad, HM; Ashraf, MI; Shabbir, A; Shahzad, M; Shamsi, S,
)
1.14
"Mefenamic acid treatment provided significant protection against the elevation of lipid peroxidation, protein oxidation, levels of TNF-α, IL-1β and Bax."( Neuroprotection by mefenamic acid against D-serine: involvement of oxidative stress, inflammation and apoptosis.
Armagan, G; Kanit, L; Turunc, E; Yalcin, A, 2012
)
1.43
"mefenamic acid for the treatment of primary dysmenorrhea."( Comparison of fennel and mefenamic acid for the treatment of primary dysmenorrhea.
Khabnadideh, S; Namavar Jahromi, B; Tartifizadeh, A, 2003
)
1.34
"Treatment with mefenamic acid resulted in less volume of blood loss compared to tranexamic acid (MD -64.26, 95% CI -105.65 to -22.87; 1 trial, 94 women; low-certainty evidence)."( Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-device use.
Christelle, K; Jaafar, SH; Norhayati, MN, 2022
)
1.06
"Treatment with mefenamic acid also significantly reduced all the hematological parameters in cyclophosphamide-induced neutropenic mice, as compared with positive control group."( Immunomodulatory activity of mefenamic acid in mice models of cell-mediated and humoral immunity.
Arshad, HM; Ashraf, MI; Shabbir, A; Shahzad, M; Shamsi, S,
)
0.76
"Treatment with mefenamic acid (10 micrograms/ml), a prostaglandin synthesis inhibitor, produced marked constriction of arterioles but not of venules, suggesting the involvement of endogenous vasodilator prostaglandins in the regulation of resting diameters of arterioles."( The influence of extracellular calcium on microvascular tone in the rat cremaster muscle.
Dowe, JP; Fleming, JT; Joshua, IG, 1988
)
0.61

Toxicity

The toxicity of the phototransformation products was evaluated using the Microtox test, which revealed that the photoproducts were more toxic than mefenamic acid for the generation of nitrosation aromatic compounds. The benefit-risk profile of meenamic acid should now be re-evaluated in light of effective and less toxic alternatives.

ExcerptReferenceRelevance
"Peptic gastroduodenal lesions due to nonsteroidal antiinflammatory drugs (NSAID) are well known, but not the adverse effects of these preparations in the lower GI tract."( [Side effects of non-steroidal antirheumatic agents in the lower gastrointestinal tract].
Güller, R, 1987
)
0.27
" We suggest that the immune complex mechanism could have induced these adverse reactions."( Serious adverse effects induced by simultaneous administration of two nonsteroidal anti-inflammatory drugs.
Awaya, N; Handa, M; Matsuyama, M; Ogino, M; Okada, H; Saruta, T; Suzuki, H; Toya, S, 1993
)
0.29
" Thirty-five subjects presented with gastrointestinal (GI) adverse events (AEs)."( Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea.
Baracat, EC; Barbosa, IC; Bedone, AJ; Camargos, A; Cortes, RJ; de Mello, NR; de Souza, RN; Martinez Alcala, FO; Rumi, DO; Tomaz, G; Velasco, JA, 2004
)
0.55
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The toxicity of the phototransformation products was evaluated using the Microtox test, which revealed that the photoproducts were more toxic than mefenamic acid for the generation of nitrosation aromatic compounds."( Phototransformation of mefenamic acid induced by nitrite ions in water: mechanism, toxicity, and degradation pathways.
Chen, P; Chen, Z; Li, F; Li, R; Liu, G; Lv, W; Ma, J; Yao, K, 2015
)
0.93
" Ecotoxicity assessment revealed that transformation by-products, particularly monohydroxylated Mfe which is more toxic than Mfe, can be formed during aqueous chlorination."( Aqueous chlorination of mefenamic acid: kinetics, transformation by-products and ecotoxicity assessment.
Adira Wan Khalit, WN; Tay, KS, 2016
)
0.74
" The benefit-risk profile of mefenamic acid should now be re-evaluated in light of effective and less toxic alternatives."( Central nervous system toxicity of mefenamic acid overdose compared with other NSAIDs: an analysis of cases reported to the United Kingdom National Poisons Information Service.
Cooper, G; Crichton, S; Eddleston, M; Kamour, A; Lupton, DJ; Thomas, SH; Thompson, JP; Vale, JA, 2017
)
1.02
" However, it has been rarely reported that, mefenamic acid can induce central nervous system toxicity both in toxic doses and therapeutic usage."( Central nervous system toxicity due to mefenamic acid.
Çaylak, ST; Doğan, NÖ; Yılmaz, S, 2019
)
1.04
" As the carboxylic acid moiety present in common NSAIDs is responsible for some of their adverse effects, but is not required for their anti-inflammatory activity, we sought to mask this group through direct coupling to glucosamine, which is thought to prevent cartilage degradation."( Molecular docking-guided synthesis of NSAID-glucosamine bioconjugates and their evaluation as COX-1/COX-2 inhibitors with potentially reduced gastric toxicity.
Hall, CD; Jones Lipinski, RA; Katritzky, AR; Morisseau, C; Sebastiano, CS; Smith, BC; Thillier, Y, 2021
)
0.62

Pharmacokinetics

The pharmacokinetic profile, including stability and release of mefenamic acid and N-hydroxymethylsuccinimide from the ester prodrug (MA-NH) was studied by RP- HPLC in acidic medium. This analysis evaluated the drug-drug interaction (DDI) following co-administration of ertugliflozin with the UGT inhibitors.

ExcerptReferenceRelevance
" These results have important implications in the determination of bioavailability and pharmacokinetic parameters of this drug."( High-performance liquid chromatographic assay of indomethacin and its application in pharmacokinetics in healthy volunteers.
Cooper, JK; Hawes, EM; McKay, G; Midha, KK, 1982
)
0.26
" The applicability of this method for pharmacokinetic studies has been established after successful application during a 12-subject bioavailabity study."( A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study.
Bhavsar, R; Dhaneshwar, S; Mahadik, M, 2012
)
0.6
" The development of NSAIDs having safer therapeutic profile depends on the better understanding of their mechanisms, physicochemical and pharmacokinetic properties."( Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
Kumar, M; Sinha, VR; Thareja, S, 2012
)
0.38
" Their similarities in therapeutic action (anti-inflammation) and metabolic pathways (phase II metabolisms) may lead to co-administration by patients with the potential of pharmacokinetic and/or pharmacodynamic interactions."( Herb-drug interactions between Scutellariae Radix and mefenamic acid: Simultaneous investigation of pharmacokinetics, anti-inflammatory effect and gastric damage in rats.
Fong, SY; Wong, YC; Xie, C; Zuo, Z, 2015
)
0.67
"The current study simultaneously monitored the pharmacokinetic and pharmacodynamic interactions in a single animal."( Herb-drug interactions between Scutellariae Radix and mefenamic acid: Simultaneous investigation of pharmacokinetics, anti-inflammatory effect and gastric damage in rats.
Fong, SY; Wong, YC; Xie, C; Zuo, Z, 2015
)
0.67
"Minimal pharmacokinetic interaction between SR extract and MEF was observed."( Herb-drug interactions between Scutellariae Radix and mefenamic acid: Simultaneous investigation of pharmacokinetics, anti-inflammatory effect and gastric damage in rats.
Fong, SY; Wong, YC; Xie, C; Zuo, Z, 2015
)
0.67
"Co-administration of SR extract and MEF potentiated the anti-inflammatory effects, alleviated the MEF-induced stomach adverse effect while having minimal pharmacokinetic interactions."( Herb-drug interactions between Scutellariae Radix and mefenamic acid: Simultaneous investigation of pharmacokinetics, anti-inflammatory effect and gastric damage in rats.
Fong, SY; Wong, YC; Xie, C; Zuo, Z, 2015
)
0.67
"The current investigation is focused on solid self-microemulsifying drug-delivery systems (S-SMEDDS) of mefenamic acid (MFA) for improving pharmacodynamic activity."( Mefenamic acid-loaded solid SMEDDS: an innovative aspect for dose reduction and improved pharmacodynamic profile.
Bedi, N; Kumar, M; Singh, D, 2019
)
2.17
" The newly developed method was successfully applied to investigate the pharmacokinetic interactions of ERTU with mefenamic acid (MEF) and ketoconazole (KET)."( A novel high-performance liquid chromatographic method combined with fluorescence detection for determination of ertugliflozin in rat plasma: Assessment of pharmacokinetic drug interaction potential of ertugliflozin with mefenamic acid and ketoconazole.
Han, DG; Yoon, IS; Yun, H, 2019
)
0.91
" This analysis evaluated the drug-drug interaction (DDI) following co-administration of ertugliflozin with the UGT inhibitor mefenamic acid (MFA) using physiologically-based pharmacokinetic (PBPK) modeling."( Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid.
Callegari, E; Goosen, TC; Lin, J; Sahasrabudhe, V; Tse, S, 2021
)
1.02

Compound-Compound Interactions

Flaxseed oil alone and in combination with mefenamic acid exhibited antiangiogenic activity both in ex vivo and in vitro. Ciprofol was safe and well tolerated when administered with meenamic acid.

ExcerptReferenceRelevance
"7 cells treated with plasma collected from control group over the 24h sampling (AUC0→24[PGE2]) was 191981±8789pg/mlhr, which was significantly reduced to 174,780±6531 and 46,225±1915pg/mlhr by plasma collected from rats administered with SR extract and MEF, respectively."( Herb-drug interactions between Scutellariae Radix and mefenamic acid: Simultaneous investigation of pharmacokinetics, anti-inflammatory effect and gastric damage in rats.
Fong, SY; Wong, YC; Xie, C; Zuo, Z, 2015
)
0.67
"25 when administered in combination with probenecid."( Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid.
Chen, J; Hanna, I; Koo, P; Majumdar, T; Mendonza, A; Meyers, D; Neelakantham, S; Rebello, S; Sunkara, G; Zhu, B, 2016
)
0.43
" Amongst the various NSAID compounds, Mefenamic acid (MEFE) and Meclofenamic acid (MECLO) showed considerable antiviral activity against viral replication individually or in combination with the common antiviral drug, Ribavirin (RIBA)."( Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo.
Abdulrahman, AY; Bahrani, H; Mohamed, Z; Othman, S; Rahman, NA; Rashid, NN; Rothan, HA; Teoh, TC; Yusof, R, 2016
)
2.15
" This analysis evaluated the drug-drug interaction (DDI) following co-administration of ertugliflozin with the UGT inhibitor mefenamic acid (MFA) using physiologically-based pharmacokinetic (PBPK) modeling."( Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid.
Callegari, E; Goosen, TC; Lin, J; Sahasrabudhe, V; Tse, S, 2021
)
1.02
" The present study evaluated the efficacy of treatment with mefenamic acid combined with standard medical care vs."( Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID‑19: A randomized double‑blind placebo‑controlled trial.
Beas-Guzman, O; Cardenas-Aguilar, CB; Chaviano-Conesa, D; Cuevas-Velazquez, AC; Delgado-Enciso, I; Delgado-Enciso, J; Delgado-Enciso, OG; Galvan-Salazar, HR; Garcia-Garcia, HS; Guzman-Esquivel, J; Guzman-Solorzano, HP; Guzman-Solorzano, JA; Martinez-Fierro, ML; Melnikov, V; Mokay-Ramirez, KA; Murillo-Zamora, E; Paz-Michel, BA; Rodriguez-Sanchez, IP; Rojas-Larios, F; Walle-Guillen, M, 2022
)
1.27
"To investigate the antiangiogenic activity of flaxseed oil alone and in combination with mefenamic acid in a dose-response study."( The Antiangiogenic Activity of Flaxseed Oil Alone and Combination with Mefenamic Acid in Vivo and in Vitro Assay.
Al-Zubaidy, NA; Sahib, HB, 2022
)
1.18
" The ex vivo rat aorta ring assay was used to screen the flaxseed oil alone and in combination with mefenamic acid for possible antiangiogenic activity."( The Antiangiogenic Activity of Flaxseed Oil Alone and Combination with Mefenamic Acid in Vivo and in Vitro Assay.
Al-Zubaidy, NA; Sahib, HB, 2022
)
1.17
" At 200, 100, and 50 µg/ml of flaxseed oil in combination with 50 µg/ml of mefenamic acid inhibited blood vessel growth with inhibition percentages of 81."( The Antiangiogenic Activity of Flaxseed Oil Alone and Combination with Mefenamic Acid in Vivo and in Vitro Assay.
Al-Zubaidy, NA; Sahib, HB, 2022
)
1.18
"Flaxseed oil alone and in combination with mefenamic acid exhibited antiangiogenic activity both in ex vivo and in vivo assays."( The Antiangiogenic Activity of Flaxseed Oil Alone and Combination with Mefenamic Acid in Vivo and in Vitro Assay.
Al-Zubaidy, NA; Sahib, HB, 2022
)
1.22
"To investigate the drug-drug interaction (DDI) of ciprofol injectable emulsion and mefenamic acid capsules in healthy subjects."( Drug-drug interaction of ciprofol injectable emulsion with mefenamic acid capsules in healthy subjects.
Hu, M; Hu, Y; Jiang, B; Lou, H; Ruan, Z; Wang, H; Xu, Y; Yan, M; Yang, D, 2023
)
1.38
" Ciprofol was safe and well tolerated when administered with mefenamic acid."( Drug-drug interaction of ciprofol injectable emulsion with mefenamic acid capsules in healthy subjects.
Hu, M; Hu, Y; Jiang, B; Lou, H; Ruan, Z; Wang, H; Xu, Y; Yan, M; Yang, D, 2023
)
1.39

Bioavailability

The bioavailability and pharmacokinetics of mefenamic acid was studied in alloxan-diabetic rabbits. methylcellulose gel containing 1% drug as coprecipitates of PVP K90 was the best among the studied formulations.

ExcerptReferenceRelevance
" It was also noted that the extent of bioavailability of mefenamic acid and its solid dispersion following oral administration was significantly greater than that following rectal administration."( Enhancement of dissolution and absorption of mefenamic acid by egg albumin.
Acartürk, F; Imai, T; Nohdomi, K; Otagiri, M, 1991
)
0.79
" The total bioavailability of tolfenamic and mefenamic acids was only slightly increased."( Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids.
Kivistö, KT; Neuvonen, PJ, 1988
)
0.77
" The bioavailability of the coated and uncoated drug was studied using four groups of animals, each consisting of six male rabbits (2-2."( Effect of encapsulation of mefenamic acid with cationic Eudragit E on its bioavailability and gastric ulcerogenic activity in rabbits.
el-Helw, A; el-Said, Y; Ramadan, EM,
)
0.43
"The influence of food on the bioavailability of mefenamic acid from two commercial capsules (products A and B) differing in bioavailability was studied with four healthy male volunteers."( Effects of food on absorption of mefenamic acid from two commercial capsules differing in bioavailability under the fasting state.
Hamaguchi, T; Mizuno, N; Shinkuma, D; Yamanaka, Y, 1987
)
0.81
"The influence of food and water intake on mefenamic acid (N-2,3-xylylanthranilic acid) bioavailability from commercial capsules of high bioavailability was studied in four healthy male volunteers."( Bioavailability of mefenamic acid: influence of food and water intake.
Hamaguchi, T; Mizuno, N; Shinkuma, D; Yamanaka, Y, 1986
)
0.86
" These results have important implications in the determination of bioavailability and pharmacokinetic parameters of this drug."( High-performance liquid chromatographic assay of indomethacin and its application in pharmacokinetics in healthy volunteers.
Cooper, JK; Hawes, EM; McKay, G; Midha, KK, 1982
)
0.26
" Although the 2 products are not equivalent regarding the secondary parameter Tmax, still the data indicate that they could be considered bioequivalent regarding rate of absorption (Cmax), extent of absorption (Cmax and AUC), and elimination (t1/2)."( Comparative bioavailability of two capsule formulations of mefenamic acid.
Jalal, IM; Najib, NM; Rawashdeh, NM, 1997
)
0.54
"The bioavailability and pharmacokinetics of mefenamic acid was studied in alloxan-diabetic rabbits."( The bioavailability and pharmacokinetics of mefenamic acid in alloxan-diabetic rabbits.
Ahmad, M; Irfan, N; Jamshaid, M; Muzaffar, NA; Qamar, S, 1997
)
0.82
" It is present in the diet, and the hepatic and duodenal sulphation might limit the bioavailability of this compound."( Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum.
De Santi, C; Mosca, F; Pacifici, GM; Pietrabissa, A; Spisni, R, 2000
)
0.31
" The bioavailability of these drugs differ among different pharmaceutical preparations and even for the same preparation."( [Variance of bioavailability of pharmaceutical preparations and analysis of factors affecting it].
Hamaguchi, T; Mizuno, N; Shinkuma, D, 2003
)
0.32
" These findings suggest that the prodrugs 3a and 3b synthesized might be used as biolabile prodrugs of mefenamic acid with increased bioavailability and less gastrointestinal side effects."( Glyceride derivatives as potential prodrugs: synthesis, biological activity and kinetic studies of glyceride derivatives of mefenamic acid.
Akhter, M; Khan, MS, 2005
)
0.75
" Considering drug release, rheological properties, and stability, methylcellulose gel containing 1% drug as coprecipitates of PVP K90 was the best among the studied formulations, was promising for improving bioavailability of mefenamic acid and can be used in future studies."( In vitro release, rheological, and stability studies of mefenamic acid coprecipitates in topical formulations.
Ahmed, TA; Fetoh, E; Ibrahim, F; Ibrahim, HM; Nutan, MT; Samy, AM, 2011
)
0.8
"The objectives of this study were to assess the bioavailability of an optimized mephenamic acid (MFA) microspheres (test) against a Ponstan® capsule (reference) in healthy volunteers, and to establish a correlation with in vitro parameters."( In vitro/in vivo correlation of fast release mephenamic acid microspheres in humans.
Ebian, AA; Etman, MA; Farid, RM; Nada, AH, 2012
)
0.38
" The relative bioavailability of the test compared to the reference capsule was 172%."( In vitro/in vivo correlation of fast release mephenamic acid microspheres in humans.
Ebian, AA; Etman, MA; Farid, RM; Nada, AH, 2012
)
0.38
"The formulation of MFA microsphere with polyethylene glycol improved the dissolution rate and bioavailability of MFA, as evidenced by a higher C(max), AUC(0-12) and AUC(0-)∞, and shorter T(max) values."( In vitro/in vivo correlation of fast release mephenamic acid microspheres in humans.
Ebian, AA; Etman, MA; Farid, RM; Nada, AH, 2012
)
0.38
"Transglycosylated stevia (stevia-G) can effectively improve the dissolution and bioavailability of poorly water-soluble drugs."( Mixed Micelle System Produced by Interaction Between Transglycosylated Stevia and an Ionic Surfactant Improves Dissolution Profile of Mefenamic Acid.
Fujimori, M; Kadota, K; Tozuka, Y, 2017
)
0.66
" While the uncertainty of its safety and the poor oral bioavailability constitute the major limiting factors of its medical use, considerable efforts including liposomal encapsulation are needed to achieve maximum therapeutic advantages."( Comparative ultrastructural hepatic alterations induced by free and liposome-encapsulated mefenamic acid.
Cheema, MS; Hakim, MN; Jarrar, QB; Zakaria, ZA,
)
0.35
" This work may help the formulator to hit the optimal solubility-permeability balance, maximizing the oral bioavailability afforded by the formulation."( Methacrylate-Copolymer Eudragit EPO as a Solubility-Enabling Excipient for Anionic Drugs: Investigation of Drug Solubility, Intestinal Permeability, and Their Interplay.
Dahan, A; Fine-Shamir, N, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Mefenamic acid was given at a dosage of 500 mg 3-times daily and piroxicam as a single daily dose of 20 mg, for a maximum of 10 days. The study suggests that adjustment of mefenamic acid dosage is not necessary in patients undergoing hemodialysis.

ExcerptRelevanceReference
" We recommend the use of MA for closure of symptomatic PDA in preterms, especially in those cases where indomethacin is not tolerated or when minute titration of its dosage is impracticable."( Therapy of symptomatic patent ductus arteriosus in preterms using mefenemic acid and indomethacin.
Merchant, RH; Sakhalkar, VS, 1992
)
0.28
" The four NSAID diclofenac, acemetacin, ibuprofen, and mefenamic acid administered to healthy volunteers at the recommended dosage led to significant suppression of thromboxane synthesis; this effect was more pronounced with acemetacin and ibuprofen than with diclofenac."( [Inhibition of thrombocyte function by non-steroidal anti-rheumatic agents: a comparative study between diclofenac, acemetacin, mefenamic acid and ibuprofen].
Raineri-Gerber, I; von Felten, A, 1991
)
0.73
" Mefenamic acid was given at a dosage of 500 mg 3-times daily and piroxicam as a single daily dose of 20 mg, for a maximum of 10 days."( A double-blind comparison of mefenamic acid and piroxicam in acute soft tissue injuries.
Haig, G, 1988
)
1.48
" The dosage of mefenamic acid was 500 mg thrice daily."( The treatment of premenstrual symptoms with mefenamic acid.
Jakubowicz, D; Wood, C, 1980
)
0.88
" The study suggests that adjustment of mefenamic acid dosage is not necessary in patients undergoing hemodialysis and that hemodialysis is of minimal value in the management of mefenamate overdose."( Hemodialysis of mefenamic acid in uremic patients.
Lee, CS; Marbury, TC; Wang, LH, 1980
)
0.88
" They were given this dosage orally at 24 h intervals."( Pharmacokinetics of mefenamic acid in preterm infants with patent ductus arteriosus.
Ito, K; Niida, Y; Owada, E; Sato, J; Umetsu, M, 1994
)
0.61
" Rings of femoral artery from heartworm-infected and noninfected control dogs were suspended in muscle baths, and dose-response relationships to endothelium-dependent (methacholine) and -independent (sodium nitroprusside) vasodilators were done."( Dirofilaria immitis: depression of endothelium-dependent relaxation of canine femoral artery seen in vivo does not persist in vitro.
Kaiser, L; Lamb, VL; Mupanomunda, M; Schwartz, AJ; Schwartz, NR; Tithof, PK; Williams, JF, 1994
)
0.29
" Dose-response curves to topically applied Krebs' solution saturated with halothane at increasing concentrations of 0%, 1%, 3% and 5% were carried out in the presence of an inhibitor of nitric oxide synthesis (N omega-nitro-L-arginine (LNA), 300 mumol litre-1) or inhibitors of prostaglandin synthesis (mefenamic acid 20 mumol litre-1 or indomethacin 20 mol litre-1) or in the absence of any inhibitor."( Role of prostaglandins and nitric oxide on halothane-induced arteriolar dilatation in rat diaphragm.
Aubier, M; Boczkowski, J; de Larminat, V; Desmonts, JM; Dureuil, B; Farinotti, R; Vicaut, E, 1996
)
0.47
" The altered bioavailability and disposition of mefenamic acid in the diabetic state will require adjustment of the dosage regimen prescribed for diabetics in a clinical setting."( The bioavailability and pharmacokinetics of mefenamic acid in alloxan-diabetic rabbits.
Ahmad, M; Irfan, N; Jamshaid, M; Muzaffar, NA; Qamar, S, 1997
)
0.81
" Each drug was given at beginning of complaint and similar dose was repeated 8 hourly at following days during the menstrual bleeding period (Total dosage used 1500 mg per day)."( Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo.
Al-Waili, NS, 2000
)
0.54
" Available conventional dosage forms are capsules and film-coated tablets."( Investigations on mefenamic acid sustained release tablets with water-insoluble gel.
Araman, A; Cevher, E; Güngör, S; Ozsoy, Y; Yildiz, A, 2003
)
0.65
" At a dosage of 100mg/kg mouse, the triterpene mixture exhibited 51% analgesic activity but only showed 20% anti-inflammatory activity."( Evaluation of the bioactivity of triterpene mixture isolated from Carmona retusa (Vahl.) Masam leaves.
Canlas, AP; Faustino, KM; Plana, KG; Villaseñor, IM, 2004
)
0.32
"Mice were dosed intraperitoneally with mefenamic acid either one day at 100mg/kg and 200mg/kg, or 14 days dosing at 50mg/kg/day and 100mg/kg/day."( Liver injury induced by the non-steroidal anti-inflammatory drug mefenamic acid.
Gan, EH; Sanat, F; Shahrin, IA; Somchit, N; Zuraini, A, 2004
)
0.83
" Log dose-response curve was obtained for each drug along with the corresponding ED(25)."( Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in adjuvant-induced arthritis in female albino rats: an isobolographic study.
Bhat, AS; Krishna, V; Kumar, D; Prakash, VR; Tandan, SK, 2007
)
0.34
" The determination of the critical concentration of disintegrant (% v/v) required for a minimum disintegration time is suggested to be useful for solid dosage form design."( Influence of loading volume of mefenamic acid on granules and tablet characteristics using a compaction simulator.
Betz, G; Kimura, G; Leuenberger, H, 2007
)
0.63
"The dose-response relation of S-methylisothiourea, rofecoxib, mefenamic acid, and their combination was studied in the late phase of formalin-induced pain in mice over the time spent in licking the hindpaw after formalin injection."( The interaction between inhibitors of nitric oxide synthase and cyclooxygenase in formalin-induced pain in mice: an isobolographic study.
Bhat, AS; Krishna, V; Kumar, D; Prakash, VR; Tandan, SK, 2008
)
0.59
" The determination of the critical concentration of disintegrant (% v/v) required for a minimum disintegration time may be useful for solid dosage form design."( Influence of loading volume of mefenamic acid on granules and tablet characteristics using a compaction simulator.
Betz, G; Kimura, G; Leuenberger, H, 2008
)
0.63
" At a dosage of 100 mg/ kg mouse, it decreased the number of squirms induced by acetic acid by 67."( Menthalactone, a new analgesic from Mentha cordifolia Opiz. Leaves.
Sanchez, AC; Villaseñor, IM,
)
0.13
" All the above parameters were found to be within the limit these indicated that the synthesized esters are good candidate for liquid dosage form."( Formulation and evaluation of suspensions: mefenamic acid prodrugs.
Mishra, P; Shah, K; Shrivastava, SK, 2014
)
0.67
" Selected "hits" were subjected to further dose-response testing, and their ability to modulate expression of UPR and oxidative stress markers was assessed by RT-PCR, Western blot, and measurement of protein carbonyl and 8-hydroxydeoxyguanosine (8-OHdG) adducts in immortalized human corneal endothelial cells (iHCECs)."( Screening and Characterization of Drugs That Protect Corneal Endothelial Cells Against Unfolded Protein Response and Oxidative Stress.
Berlinicke, CA; Jun, AS; Jurkunas, U; Kim, EC; Toyono, T; Usui, T; Zack, DJ, 2017
)
0.46
"Drug load plays an important role in the development of solid dosage forms, since it can significantly influence both processability and final product properties."( Influence of drug load on dissolution behavior of tablets containing a poorly water-soluble drug: estimation of the percolation threshold.
Kleinebudde, P; Stillhart, C; Szepes, A; Wenzel, T, 2017
)
0.46
" Moreover ,the proposed methods were successfully applied for determination of the studied drug in its pharmaceutical dosage form."( Different Chromatographic Methods for Simultaneous Determination of Mefenamic Acid and Two of Its Toxic Impurities.
Abdelwahab, NS; Ali, NW; Elsaady, MT; Morcoss, MM, 2017
)
0.69
" The optimized liquid SMEDD formulation was spray dried to solid dosage form and observed with enhanced amorphization or molecular dispersion of MFA in S-SMEDDS, as evident from x-ray diffractometry and differential scanning calorimetry studies."( Mefenamic acid-loaded solid SMEDDS: an innovative aspect for dose reduction and improved pharmacodynamic profile.
Bedi, N; Kumar, M; Singh, D, 2019
)
1.96
" This study illustrates advantages of applying a structured development program aimed at retaining API physical properties in the final dosage form."( Improving Consistency for a Mefenamic Acid Immediate Release Formulation.
Halbert, GW; Prasad, E; Robertson, J, 2020
)
0.85
" As a guide to determining dosing regimens in pediatric studies, the verified PBPK model, along with UGT enzyme ontogeny maturation understanding, was used for predictions of dapagliflozin monotherapy exposures in pediatric subjects aged 1 month to 18 years that best matched exposure in adult patients with a 10-mg single dose of dapagliflozin."( Model-Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes.
Boulton, DW; Jo, H; Parkinson, J; Pilla Reddy, V; Tang, W, 2021
)
0.62
"69 mg/g) is achieved under an extremely low DHQU dosage (0."( Efficient removal of mefenamic acid and ibuprofen on organo-Vts with a quinoline-containing gemini surfactant: Adsorption studies and model calculations.
Ding, F; Gao, M; Han, T; Mao, S; Shen, T; Zhao, Q, 2022
)
1.04
"To investigate the antiangiogenic activity of flaxseed oil alone and in combination with mefenamic acid in a dose-response study."( The Antiangiogenic Activity of Flaxseed Oil Alone and Combination with Mefenamic Acid in Vivo and in Vitro Assay.
Al-Zubaidy, NA; Sahib, HB, 2022
)
1.18
" Also, the assay was used to determine the dose-response effect."( The Antiangiogenic Activity of Flaxseed Oil Alone and Combination with Mefenamic Acid in Vivo and in Vitro Assay.
Al-Zubaidy, NA; Sahib, HB, 2022
)
0.95
" In this study, three chemometric techniques were compared to seven univariate techniques to resolve a mixture of mefenamic acid and febuxostat in their raw materials, dosage forms and spiked human plasma."( Multi-spectroscopic assay methods for concurrent determination of recent anti-gout combination, a comparative study.
Abdallah, NA; El-Brashy, AM; Fathy, ME; Ibrahim, FA; Tolba, MM, 2023
)
1.12
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
analgesicAn agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
antirheumatic drugA drug used to treat rheumatoid arthritis.
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
antipyreticA drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitorA compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminobenzoic acid
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Mefenamic Acid Action Pathway2967

Protein Targets (83)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.22560.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.01120.004023.8416100.0000AID485290
LuciferasePhotinus pyralis (common eastern firefly)Potency36.99570.007215.758889.3584AID1224835; AID588342; AID624030
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency5.46813.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency76.95880.006038.004119,952.5996AID1159521
SMAD family member 2Homo sapiens (human)Potency21.59310.173734.304761.8120AID1346859; AID1346924
GLS proteinHomo sapiens (human)Potency16.19360.35487.935539.8107AID624170
SMAD family member 3Homo sapiens (human)Potency21.59310.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency12.43470.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.70780.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency18.07120.000221.22318,912.5098AID588516; AID743035; AID743036; AID743053; AID743063
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency10.00000.00137.762544.6684AID914; AID915
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency11.13670.000657.913322,387.1992AID1259377; AID1259378
progesterone receptorHomo sapiens (human)Potency24.02330.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency17.37680.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency1.99530.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency44.66840.000214.376460.0339AID588532
retinoid X nuclear receptor alphaHomo sapiens (human)Potency41.72600.000817.505159.3239AID1159527; AID588544
farnesoid X nuclear receptorHomo sapiens (human)Potency7.07950.375827.485161.6524AID588527
pregnane X nuclear receptorHomo sapiens (human)Potency55.82670.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency24.71080.000229.305416,493.5996AID588513; AID588514; AID743069; AID743075; AID743078; AID743079
GVesicular stomatitis virusPotency27.54040.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency33.20590.001024.504861.6448AID588534; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency40.55040.001019.414170.9645AID588537; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency20.00990.023723.228263.5986AID588543; AID743222; AID743223
Histone H2A.xCricetulus griseus (Chinese hamster)Potency113.00400.039147.5451146.8240AID1224845
cytochrome P450 2C9 precursorHomo sapiens (human)Potency7.94330.00636.904339.8107AID883
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency20.81140.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency28.18383.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency32.87850.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency40.72260.000627.21521,122.0200AID651741; AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency22.14270.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency11.29470.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency27.54040.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency7.94330.00638.235039.8107AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency1.58490.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)Potency35.48130.015823.527344.6684AID651778
GABA theta subunitRattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency11.29471.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Aldo-keto reductase family 1 member B10Homo sapiens (human)IC50 (µMol)1.60000.00101.94459.6000AID1199060
Transient receptor potential cation channel subfamily M member 2Homo sapiens (human)IC50 (µMol)124.00000.21001.89115.0000AID1065922
Bile salt export pumpHomo sapiens (human)IC50 (µMol)95.00000.11007.190310.0000AID1443986; AID1473738
Dihydrofolate reductaseHomo sapiens (human)Ki72.00000.00000.37564.9000AID1660990
Beta-lactamaseEscherichia coli K-12IC50 (µMol)350.00000.01502.46578.0000AID43431
Myc proto-oncogene proteinHomo sapiens (human)IC50 (µMol)403.00001.00005.73259.6700AID1634394
MyeloperoxidaseHomo sapiens (human)IC50 (µMol)1.59500.02001.88117.6800AID1446226; AID1446231
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1210069
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)77.00000.00101.191310.0000AID1199061
Aldo-keto reductase family 1 member C4Homo sapiens (human)IC50 (µMol)100.00002.30004.86338.2500AID729956
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)12.55800.00021.557410.0000AID625243; AID729957
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)1.75100.00010.995010.0000AID625244; AID729955
Aldo-keto reductase family 1 member C3Homo sapiens (human)IC50 (µMol)0.56000.05002.207010.0000AID729959
Aldo-keto reductase family 1 member C3Homo sapiens (human)Ki0.30000.00590.70913.1000AID703561
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)50.00000.01202.53129.4700AID1210069
Aldo-keto reductase family 1 member C2 Homo sapiens (human)IC50 (µMol)6.97000.37004.09519.2800AID729958
Aldo-keto reductase family 1 member C2 Homo sapiens (human)Ki0.22000.00590.37312.8000AID703562
Aldo-keto reductase family 1 member C1Homo sapiens (human)IC50 (µMol)3.91000.00603.12657.9000AID729960
Aldo-keto reductase family 1 member C1Homo sapiens (human)Ki0.81000.00590.56752.8000AID703563
Nicotinate phosphoribosyltransferaseHomo sapiens (human)Ki0.00000.00000.00060.0019AID1618606
NACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)IC50 (µMol)25.00000.00041.441910.0000AID1527568
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glycogen synthase kinase-3 beta isoform 1Homo sapiens (human)EC50 (µMol)300.00000.212522.156283.9400AID434954
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)31.19860.00033.166210.0000AID1549771; AID1549781
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (346)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
cellular detoxification of aldehydeAldo-keto reductase family 1 member B10Homo sapiens (human)
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature homeostasisTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
dendritic cell chemotaxisTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
response to heatTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
response to purine-containing compoundTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
regulation of actin cytoskeleton organizationTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
response to hydroperoxideTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
sodium ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
release of sequestered calcium ion into cytosolTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
regulation of filopodium assemblyTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to calcium ionTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to purine-containing compoundTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
manganese ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to temperature stimulusTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
zinc ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
dendritic cell differentiationTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion transmembrane import into cytosolTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion import across plasma membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
antibiotic catabolic processBeta-lactamaseEscherichia coli K-12
response to antibioticBeta-lactamaseEscherichia coli K-12
positive regulation of cell population proliferationMyc proto-oncogene proteinHomo sapiens (human)
regulation of gene expressionMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationMyc proto-oncogene proteinHomo sapiens (human)
G1/S transition of mitotic cell cycleMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
MAPK cascadeMyc proto-oncogene proteinHomo sapiens (human)
branching involved in ureteric bud morphogenesisMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of mesenchymal cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
chromatin remodelingMyc proto-oncogene proteinHomo sapiens (human)
intracellular iron ion homeostasisMyc proto-oncogene proteinHomo sapiens (human)
DNA damage responseMyc proto-oncogene proteinHomo sapiens (human)
response to xenobiotic stimulusMyc proto-oncogene proteinHomo sapiens (human)
response to gamma radiationMyc proto-oncogene proteinHomo sapiens (human)
regulation of cell cycle processMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of gene expressionMyc proto-oncogene proteinHomo sapiens (human)
regulation of telomere maintenanceMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of stress-activated MAPK cascadeMyc proto-oncogene proteinHomo sapiens (human)
protein-DNA complex disassemblyMyc proto-oncogene proteinHomo sapiens (human)
cellular response to UVMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
fibroblast apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of monocyte differentiationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of fibroblast proliferationMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of fibroblast proliferationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of epithelial cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
chromosome organizationMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of cell divisionMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of telomerase activityMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of transcription initiation by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
ERK1 and ERK2 cascadeMyc proto-oncogene proteinHomo sapiens (human)
response to growth factorMyc proto-oncogene proteinHomo sapiens (human)
cellular response to hypoxiaMyc proto-oncogene proteinHomo sapiens (human)
cellular response to xenobiotic stimulusMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of metanephric cap mesenchymal cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway by p53 class mediatorMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of miRNA transcriptionMyc proto-oncogene proteinHomo sapiens (human)
regulation of somatic stem cell population maintenanceMyc proto-oncogene proteinHomo sapiens (human)
regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of cell population proliferationMyc proto-oncogene proteinHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
hydrogen peroxide catabolic processMyeloperoxidaseHomo sapiens (human)
response to yeastMyeloperoxidaseHomo sapiens (human)
hypochlorous acid biosynthetic processMyeloperoxidaseHomo sapiens (human)
respiratory burst involved in defense responseMyeloperoxidaseHomo sapiens (human)
defense responseMyeloperoxidaseHomo sapiens (human)
response to oxidative stressMyeloperoxidaseHomo sapiens (human)
response to mechanical stimulusMyeloperoxidaseHomo sapiens (human)
removal of superoxide radicalsMyeloperoxidaseHomo sapiens (human)
response to foodMyeloperoxidaseHomo sapiens (human)
response to lipopolysaccharideMyeloperoxidaseHomo sapiens (human)
low-density lipoprotein particle remodelingMyeloperoxidaseHomo sapiens (human)
hydrogen peroxide catabolic processMyeloperoxidaseHomo sapiens (human)
negative regulation of apoptotic processMyeloperoxidaseHomo sapiens (human)
defense response to fungusMyeloperoxidaseHomo sapiens (human)
response to gold nanoparticleMyeloperoxidaseHomo sapiens (human)
defense response to bacteriumMyeloperoxidaseHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid biosynthetic processAldo-keto reductase family 1 member C4Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
androgen metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid and bile salt transportAldo-keto reductase family 1 member C4Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C4Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
gluconeogenesisMalate dehydrogenase, cytoplasmicHomo sapiens (human)
NADH metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
NADP metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
malate metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
oxaloacetate metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
tricarboxylic acid cycleMalate dehydrogenase, cytoplasmicHomo sapiens (human)
malate-aspartate shuttleMalate dehydrogenase, cytoplasmicHomo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
G protein-coupled receptor signaling pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
response to nutrientAldo-keto reductase family 1 member C3Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of cell population proliferationAldo-keto reductase family 1 member C3Homo sapiens (human)
male gonad developmentAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to starvationAldo-keto reductase family 1 member C3Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
cyclooxygenase pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
keratinocyte differentiationAldo-keto reductase family 1 member C3Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
retinal metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
macromolecule metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
regulation of retinoic acid receptor signaling pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
renal absorptionAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to calcium ionAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to prostaglandin stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to corticosteroid stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to prostaglandin D stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
negative regulation of retinoic acid biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
regulation of testosterone biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of endothelial cell apoptotic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
G protein-coupled receptor signaling pathwayAldo-keto reductase family 1 member C2 Homo sapiens (human)
digestionAldo-keto reductase family 1 member C2 Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
positive regulation of cell population proliferationAldo-keto reductase family 1 member C2 Homo sapiens (human)
epithelial cell differentiationAldo-keto reductase family 1 member C2 Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAldo-keto reductase family 1 member C2 Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C2 Homo sapiens (human)
cellular response to prostaglandin D stimulusAldo-keto reductase family 1 member C2 Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
xenobiotic metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
digestionAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid and bile salt transportAldo-keto reductase family 1 member C1Homo sapiens (human)
intestinal cholesterol absorptionAldo-keto reductase family 1 member C1Homo sapiens (human)
epithelial cell differentiationAldo-keto reductase family 1 member C1Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
retinal metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
cholesterol homeostasisAldo-keto reductase family 1 member C1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
response to organophosphorusAldo-keto reductase family 1 member C1Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to oxidative stressNicotinate phosphoribosyltransferaseHomo sapiens (human)
NAD salvageNicotinate phosphoribosyltransferaseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (158)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B10Homo sapiens (human)
alcohol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
hydrolase activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
ADP-ribose diphosphatase activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
monoatomic cation channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
sodium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
manganese ion transmembrane transporter activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion bindingTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
mono-ADP-D-ribose bindingTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
ligand-gated calcium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
beta-lactamase activityBeta-lactamaseEscherichia coli K-12
hydrolase activityBeta-lactamaseEscherichia coli K-12
RNA polymerase II cis-regulatory region sequence-specific DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
core promoter sequence-specific DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
transcription coregulator bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
protein bindingMyc proto-oncogene proteinHomo sapiens (human)
identical protein bindingMyc proto-oncogene proteinHomo sapiens (human)
protein-containing complex bindingMyc proto-oncogene proteinHomo sapiens (human)
protein dimerization activityMyc proto-oncogene proteinHomo sapiens (human)
E-box bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription factor bindingMyc proto-oncogene proteinHomo sapiens (human)
SCF ubiquitin ligase complex bindingMyc proto-oncogene proteinHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
chromatin bindingMyeloperoxidaseHomo sapiens (human)
peroxidase activityMyeloperoxidaseHomo sapiens (human)
protein bindingMyeloperoxidaseHomo sapiens (human)
heparin bindingMyeloperoxidaseHomo sapiens (human)
heme bindingMyeloperoxidaseHomo sapiens (human)
metal ion bindingMyeloperoxidaseHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C4Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid transmembrane transporter activityAldo-keto reductase family 1 member C4Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C4Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
testosterone dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
chlordecone reductase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C4Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
malic enzyme activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
protein bindingMalate dehydrogenase, cytoplasmicHomo sapiens (human)
L-malate dehydrogenase activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
diiodophenylpyruvate reductase activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
hydroxyphenylpyruvate reductase activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C3Homo sapiens (human)
all-trans-retinol dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C3Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin D2 11-ketoreductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
ketoreductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin-F synthase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
15-hydroxyprostaglandin-D dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
Delta4-3-oxosteroid 5beta-reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C3Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C2 Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
carboxylic acid bindingAldo-keto reductase family 1 member C2 Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C2 Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C1Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C1Homo sapiens (human)
carboxylic acid bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
3beta-hydroxy-5beta-steroid dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorAldo-keto reductase family 1 member C1Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androsterone dehydrogenase (B-specific) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nicotinate phosphoribosyltransferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
transferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
metal ion bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (62)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
extracellular regionAldo-keto reductase family 1 member B10Homo sapiens (human)
lysosomeAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
mitochondrionAldo-keto reductase family 1 member B10Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
lysosomeTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
lysosomal membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cytoplasmic vesicle membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
specific granule membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cell projectionTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
perikaryonTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
tertiary granule membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
ficolin-1-rich granule membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
outer membrane-bounded periplasmic spaceBeta-lactamaseEscherichia coli K-12
periplasmic spaceBeta-lactamaseEscherichia coli K-12
nucleusMyc proto-oncogene proteinHomo sapiens (human)
nucleoplasmMyc proto-oncogene proteinHomo sapiens (human)
nucleolusMyc proto-oncogene proteinHomo sapiens (human)
cytoplasmMyc proto-oncogene proteinHomo sapiens (human)
Myc-Max complexMyc proto-oncogene proteinHomo sapiens (human)
RNA polymerase II transcription repressor complexMyc proto-oncogene proteinHomo sapiens (human)
chromatinMyc proto-oncogene proteinHomo sapiens (human)
protein-containing complexMyc proto-oncogene proteinHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionMyeloperoxidaseHomo sapiens (human)
extracellular spaceMyeloperoxidaseHomo sapiens (human)
nucleusMyeloperoxidaseHomo sapiens (human)
nucleoplasmMyeloperoxidaseHomo sapiens (human)
lysosomeMyeloperoxidaseHomo sapiens (human)
secretory granuleMyeloperoxidaseHomo sapiens (human)
azurophil granule lumenMyeloperoxidaseHomo sapiens (human)
azurophil granuleMyeloperoxidaseHomo sapiens (human)
intracellular membrane-bounded organelleMyeloperoxidaseHomo sapiens (human)
extracellular exosomeMyeloperoxidaseHomo sapiens (human)
phagocytic vesicle lumenMyeloperoxidaseHomo sapiens (human)
extracellular spaceMyeloperoxidaseHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
cytoplasmAldo-keto reductase family 1 member C4Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C4Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C4Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
extracellular spaceMalate dehydrogenase, cytoplasmicHomo sapiens (human)
cytoplasmMalate dehydrogenase, cytoplasmicHomo sapiens (human)
centrosomeMalate dehydrogenase, cytoplasmicHomo sapiens (human)
cytosolMalate dehydrogenase, cytoplasmicHomo sapiens (human)
extracellular exosomeMalate dehydrogenase, cytoplasmicHomo sapiens (human)
cytosolMalate dehydrogenase, cytoplasmicHomo sapiens (human)
nucleusAldo-keto reductase family 1 member C3Homo sapiens (human)
cytoplasmAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C3Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C3Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C2 Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolAldo-keto reductase family 1 member C1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C1Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
extracellular regionNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
azurophil granule lumenNicotinate phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (221)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1065922Inhibition of human recombinant TRPM22013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationship of adenosine 5'-diphosphoribose at the transient receptor potential melastatin 2 (TRPM2) channel: rational design of antagonists.
AID1199061Inhibition of human AR by fluorescence assay2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
AID161313Mean maximal plasma concentration2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID26962Calculated partition coefficient (clogP)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Thyroid hormone uptake by hepatocytes: structure-activity relationships of phenylanthranilic acids with inhibitory activity.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1222962Drug metabolism in rat hepatocytes assessed as MFA-SCoA by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID52771Fold increase in IC50 vs chymotrypsinogen with 0.1 mg/ml saponin2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1667991Inhibition of recombinant human PDE4B expressed in baculovirus infected Sf9 cells at 10 uM using [3H] cAMP as substrate after 30 min by scintillation proximity assay relative to control2020Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10
Ultrasound assisted rapid synthesis of mefenamic acid based indole derivatives under ligand free Cu-catalysis: Their pharmacological evaluation.
AID1549771Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID429545Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 hr2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
Chlorzoxazone esters of some non-steroidal anti-inflammatory (NSAI) carboxylic acids as mutual prodrugs: design, synthesis, pharmacological investigations and docking studies.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1222968Drug metabolism in rat hepatocytes assessed as I-SG thioester at 100 uM at 10 mins incubation by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1486519Binding affinity to transthyretin in human blood plasma assessed as plasma binding selectivity by measuring stoichiometry of small molecule bound to TTR incubated for 24 hrs at 37 degC by RP-HPLC2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID1763929Inhibition of COX-1 (unknown origin)2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 43Green synthesis of therapeutically active 1,3,4-oxadiazoles as antioxidants, selective COX-2 inhibitors and their in silico studies.
AID106802Fold decrease in IC50 vs malate dehydrogenase (MDH) on pre-incubation2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID294920Antiinflammatory activity in Albino rat assessed as protection against carrageenan-induced hind paw oedema at 100 mg/kg, po after 3 hrs2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Syntheses of new tetrasubstituted thiophenes as novel anti-inflammatory agents.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1739641Antimycobacterial activity activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of microbial growth incubated for 4 weeks in culture medium at pH 6.82020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID429546Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 2 hrs2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
Chlorzoxazone esters of some non-steroidal anti-inflammatory (NSAI) carboxylic acids as mutual prodrugs: design, synthesis, pharmacological investigations and docking studies.
AID1446231Inhibition of recombinant MPO (unknown origin) assessed as reduction in LDL oxidation in presence of H2O2 and HCl after 5 mins by ELISA2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID604519Antipyretic activity against IL-1beta-induced hyperthermia in rat assessed as change in rectal temperature at 100 mg/kg, icv measured after 2 hrs2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1656360Half life in potassium phosphate buffer by liquid chromatography-tandem mass spectrometry2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Designing around Structural Alerts in Drug Discovery.
AID1446229Inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation by measuring residual activity at 5 uM in presence of H2O2 incubated for 5 mins followed by 100 fold enzyme dilution relative to control2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID43563Fold decrease in IC50 vs beta-lactamase on pre-incubation2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID677462Dissociation constant, pKa of the compound2012European journal of medicinal chemistry, Jul, Volume: 53Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID729957Inhibition of COX1 (unknown origin)2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
AID624661Inhibition of mycophenolic acid (0.5 mM) glucuronidation by human kidney microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1446257Permeability of the compound in human Caco2 cells2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID703561Inhibition of human recombinant AKR1C3 assessed as 1-acenaphthenol oxidation by spectrophotometry2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
AID1222949Drug metabolism in human hepatocytes assessed as MFA-SCoA at 100 uM by reverse phase LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID429544Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 0.5 hrs2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
Chlorzoxazone esters of some non-steroidal anti-inflammatory (NSAI) carboxylic acids as mutual prodrugs: design, synthesis, pharmacological investigations and docking studies.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID52778Fold decrease in IC50 vs chymotrypsinogen on pre-incubation2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1549781Agonist activity at human TRPA1 in WI38 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID729956Inhibition of AKR1C4 (unknown origin)2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
AID263727Drug level in mouse brain at 50 mg/kg, po2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
AID729955Inhibition of COX2 (unknown origin)2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID218695Fold increase in IC50 vs beta-lactamase with 10x increased enzyme2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1144132Increase in mollusk membrane potential assessed as concentration required to raise 20 mV1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
On the structure of medicinal chemistry.
AID1660990Inhibition of human DHFR in presence of DHF and NADPH by UV-vis spectrometry by Lineweaver-Burk plot analysis2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.
AID182195Compound was tested for antiinflammatory activity and the % inhibition was reported 3 h after carrageenan injection in the hind paw edema test in rats: dose=40 mg/kg, p.o.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Studies on heterocyclic compounds. 6. Synthesis and analgesic and antiinflammatory activities of 3,4-dimethylpyrano[2,3-c]pyrazol-6-one derivatives.
AID624662Inhibition of mycophenolic acid (1 mM) glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID574423Displacement of 4-fluorophenyl 3-(4-hydroxy-3,5-dimethylstyryl)benzoate from recombinant TTR assessed as fluorescence at 37 degC after 3 hrs2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.
AID1222950Drug metabolism in rat hepatocytes assessed as MFA-SG at 100 uM by sensitive LC-MS/MS MRM analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID218693Fold increase in IC50 vs beta-lactamaase with 1 mg/mL saponin2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1199060Inhibition of wild-type N-terminal 6-His tagged AKR1B10 (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as pyridine-3-aldehyde reduction by spectrophotometry2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
AID1222955Drug metabolism in rat hepatocytes assessed as acyl migration isomers at 100 uM by positive ion LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID106800Fold increase in IC50 vs malate dehydrogenase (MDH) with 1 mg/ml saponin; increase2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID52792Compound was tested for the inhibition of Chymotrypsinogen at 400 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1307705Activation of TREK1 (unknown origin) expressed in HEK293 cells assessed as increase in current density at 100 uM relative to control2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
AID703562Inhibition of human recombinant AKR1C2 assessed as 1-acenaphthenol oxidation by spectrophotometry2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
AID112288Compound was tested for antianalgesic activity by phenylquinone writhing method in mice.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Studies on heterocyclic compounds. 6. Synthesis and analgesic and antiinflammatory activities of 3,4-dimethylpyrano[2,3-c]pyrazol-6-one derivatives.
AID263728Drug level in mouse plasma at 50 mg/kg, po2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
AID558029Antiviral activity against JC polyomavirus M1/SVEdelta infected in human SVG-A cells assessed as inhibition of viral replication after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID558031Drug concentration in human plasma2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1446235Inhibition of bovine milk LPO assessed as reduction in NaOSCN production in presence of H2O2/NaSCN after 5 mins2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID43431Compound was tested for the inhibition of beta-lactamase2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID729960Inhibition of AKR1C1 (unknown origin)2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
AID1549812Agonist activity at human TRPA1 Phe909Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 30 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1667993Inhibition of PDE4D2 (unknown origin) at 30 uM relative to control2020Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10
Ultrasound assisted rapid synthesis of mefenamic acid based indole derivatives under ligand free Cu-catalysis: Their pharmacological evaluation.
AID729959Inhibition of AKR1C3 (unknown origin)2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
AID574422Inhibition of wild type-TTR expressed in Escherichia coli assessed as amyloid fibril formation at pH 4.4 at 7. 2 uM after 72 hrs by acid-mediated aggregation assay relative to control2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.
AID429549Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 5 hrs2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
Chlorzoxazone esters of some non-steroidal anti-inflammatory (NSAI) carboxylic acids as mutual prodrugs: design, synthesis, pharmacological investigations and docking studies.
AID703563Inhibition of human recombinant AKR1C1 assessed as 1-acenaphthenol oxidation by spectrophotometry2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
AID429547Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
Chlorzoxazone esters of some non-steroidal anti-inflammatory (NSAI) carboxylic acids as mutual prodrugs: design, synthesis, pharmacological investigations and docking studies.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1222954Drug metabolism in rat hepatocytes assessed as MFA-1-beta-O-G at 100 uM by positive ion LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID78389Compound is evaluated for the inhibition of [125I]T3 uptake by H4 rat hepatoma cells at 0.1 mM1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Thyroid hormone uptake by hepatocytes: structure-activity relationships of phenylanthranilic acids with inhibitory activity.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID558036Therapeutic index, ratio of TC50 for JC polyomavirus M1/SVEdelta infected human SVG-A cells to EC50 for JC polyomavirus M1/SVEdelta2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID1272494Anti-inflammatory activity in rat assessed as reduction of carrageenan-induced paw edema at 150 umol/kg, ip after 3.5 hrs relative to control2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Amides of non-steroidal anti-inflammatory drugs with thiomorpholine can yield hypolipidemic agents with improved anti-inflammatory activity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1446226Inhibition of recombinant MPO (unknown origin) assessed as reduction in taurine chloramine production preincubated with enzyme and taurine followed by H2O2 addition measured after 5 mins2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1446260Substrate activity at CYP2C9 (unknown origin)2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1446261Acute toxicity in rat2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID263729Ratio of drug level in brain against plasma in mice at 50 mg/kg, po2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
AID1221821Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1222986Drug level in Sprague-Dawley rat bile treated with 100 mg/kg, ip MFA after 6 hrs by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1763931Selectivity index, ratio of IC50 for COX-1 (unknown origin) to IC50 for COX-2 (unknown origin)2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 43Green synthesis of therapeutically active 1,3,4-oxadiazoles as antioxidants, selective COX-2 inhibitors and their in silico studies.
AID1222951Drug metabolism in human hepatocytes assessed as MFA-SG at 100 uM by sensitive LC-MS/MS MRM analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1256770Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw oedema at 0.15 mmol/kg, ip administered 5 mins before carrageenan challenge measured after 3.5 hrs2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Esters of some non-steroidal anti-inflammatory drugs with cinnamyl alcohol are potent lipoxygenase inhibitors with enhanced anti-inflammatory activity.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID558037Cytotoxicity against human SVG-A cells2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID1446228Inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation by measuring residual activity at 5 uM in absence of H2O2 incubated for 5 mins followed by 100 fold enzyme dilution relative to control2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1446230Inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation by measuring residual activity at 5 uM in presence of H2O2 and NaCl incubated for 5 mins followed by 100 fold enzyme dilution relative to control2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1527568Inhibition of NLRP3 inflammasome activation in LPS-primed C57BL/6 mouse bone marrow derived macrophages preincubated for 15 mins followed by addition of ATP and measured after 1 hr by ELISA2020European journal of medicinal chemistry, Jan-01, Volume: 185Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID558030Drug concentration in human brain2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID1144131Lipophilicity, log P of the compound1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
On the structure of medicinal chemistry.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1446256Selectivity ratio of IC50 for bovine milk LPO to IC50 for recombinant MPO (unknown origin)2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1486518Inhibition of acid-induced wild type transthyretin (unknown origin) aggregation expressed in Escherichia coli pre-incubated for 30 mins before acid addition and further incubated for 72 hrs at 37 degC under dark conditions by UV-Vis spectrophotometry2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID429548Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 4 hrs2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
Chlorzoxazone esters of some non-steroidal anti-inflammatory (NSAI) carboxylic acids as mutual prodrugs: design, synthesis, pharmacological investigations and docking studies.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1763930Inhibition of COX-2 (unknown origin)2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 43Green synthesis of therapeutically active 1,3,4-oxadiazoles as antioxidants, selective COX-2 inhibitors and their in silico studies.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1222947Drug metabolism in rat hepatocytes assessed as MFA-SCoA at 100 uM by reverse phase LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID729958Inhibition of AKR1C2 (unknown origin)2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
AID574424Displacement of S-phenyl 3-(4-hydroxy-3,5-dimethylstyryl)benzothioate from human TTR assessed as fluorescence at 37 degC after 3 hrs2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.
AID106801Inhibition of malate dehydrogenase (MDH)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345284Human COX-1 (Cyclooxygenase)2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
AID1345206Human COX-2 (Cyclooxygenase)2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
AID1346619Human TRPM3 (Transient Receptor Potential channels)2011British journal of pharmacology, Apr, Volume: 162, Issue:8
Fenamates as TRP channel blockers: mefenamic acid selectively blocks TRPM3.
AID1346723Human Kv7.1 (Voltage-gated potassium channels)2001Cell, Jan-26, Volume: 104, Issue:2
MiRP2 forms potassium channels in skeletal muscle with Kv3.4 and is associated with periodic paralysis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,104)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990513 (46.47)18.7374
1990's143 (12.95)18.2507
2000's154 (13.95)29.6817
2010's225 (20.38)24.3611
2020's69 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 121.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index121.21 (24.57)
Research Supply Index7.20 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index227.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (121.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials158 (13.39%)5.53%
Reviews51 (4.32%)6.00%
Case Studies104 (8.81%)4.05%
Observational0 (0.00%)0.25%
Other867 (73.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
International, Prospective, Double-blind, 3-arm Comparative, Randomized, Placebo-controlled Phase IV Study on the Effect of Counseling and Either Tranexamic Acid or Mefenamic Acid or Placebo, on the Management of Bleeding/Spotting in Women Using the Levon [NCT01295294]Phase 4187 participants (Actual)Interventional2011-03-31Completed
Role of DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis [NCT01942122]Phase 2/Phase 360 participants (Actual)Interventional2015-10-31Completed
Double Blind Study to Evaluate Efficacy and Safety of Meloxicam 7.5 mg and 15 mg Versus Mefenamic Acid 1500 mg in the Treatment of Dysmenorrhea [NCT02183025]Phase 2337 participants (Actual)Interventional1998-01-31Completed
Open-label, Cross Over, Single-sequence, Two Periods Phase 1 Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose Mefenamic Acid, a Known UGT1A9 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Single-dose Sotagliflozin in Health [NCT03070678]Phase 116 participants (Actual)Interventional2017-03-14Completed
A Phase 1, Open-Label Study to Evaluate the Effect of Itraconazole and Mefenamic Acid on the Single-Dose Pharmacokinetic Profile of Soticlestat in Healthy Participants [NCT05064449]Phase 128 participants (Actual)Interventional2021-10-14Completed
Efficacy of Pain Control Following Root Canal Treatment Using Paracetamol Alone and in Combination With Three Different Non-Steroidal Anti-Inflammatory Analgesics [NCT02417337]Phase 2170 participants (Actual)Interventional2012-08-31Completed
Efficacy of Mefenamic Acid and Hyoscine for Pain Relief During Saline Infusion Sonohysterography in Infertile Women. A Double Blind Randomized Controlled Trial [NCT01060696]138 participants (Anticipated)Interventional2009-01-31Active, not recruiting
Combined Oral Contraceptives, Progestogens, and Non-steroidal Anti-inflammatory Drugs for Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause [NCT02943655]Phase 3240 participants (Actual)Interventional2017-11-01Completed
The Efficacy of Ayurved Siriraj Prasaplai for Treatment Primary Dysmenorrhea [NCT01598012]Phase 440 participants (Actual)Interventional2011-12-31Completed
A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of Uridine 5'-Diphosphate-glucuronosyltransferases (UGTs) on the Pharmacokinetics of Ecopipam Tablets and Its Active Metabolite (EBS-101-40853) in Heal [NCT04902105]Phase 138 participants (Actual)Interventional2021-05-13Completed
Preemptive Analgesia for Primary Dysmenorrhoea: a Randomized Controlled Trial [NCT03323671]Phase 2/Phase 384 participants (Actual)Interventional2017-08-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT05064449 (13) [back to overview]Part 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Soticlestat When Administered Alone and With Itraconazole
NCT05064449 (13) [back to overview]Part 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat When Administered Alone and With Itraconazole
NCT05064449 (13) [back to overview]Part 1, Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Itraconazole
NCT05064449 (13) [back to overview]Part 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Soticlestat When Administered Alone and With Itraconazole
NCT05064449 (13) [back to overview]Part 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Soticlestat When Administered Alone and With Mefenamic Acid
NCT05064449 (13) [back to overview]Part 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat When Administered Alone and With Mefenamic Acid
NCT05064449 (13) [back to overview]Part 2, Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Mefenamic Acid
NCT05064449 (13) [back to overview]Part 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Soticlestat When Administered Alone and With Mefenamic Acid
NCT05064449 (13) [back to overview]Parts 1 and 2: Number of Participants Reported One or More Treatment-emergent Adverse Event (TEAE)
NCT05064449 (13) [back to overview]Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Electrocardiogram (ECG)
NCT05064449 (13) [back to overview]Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Laboratory Evaluations
NCT05064449 (13) [back to overview]Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Vital Signs
NCT05064449 (13) [back to overview]Parts 1 and 2: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)

Part 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Soticlestat When Administered Alone and With Itraconazole

(NCT05064449)
Timeframe: Soticlestat alone: Period 1, Day 1 pre-dose and at multiple timepoints (up to 96 hours) post-dose; Soticlestat with itraconazole: Period 2, Day 5 pre-dose and at multiple timepoints (up to 168 hours) post-dose

Interventionnanogram*hours per milliliter(ng*hr/mL) (Geometric Mean)
Part 1: Soticlestat 300 mg Alone1483
Part 1: Soticlestat 300 mg + Itraconazole 200 mg1914

[back to top]

Part 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat When Administered Alone and With Itraconazole

(NCT05064449)
Timeframe: Soticlestat alone: Period 1, Day 1 pre-dose and at multiple timepoints (up to 96 hours) post-dose; Soticlestat with itraconazole: Period 2, Day 5 pre-dose and at multiple timepoints (up to 168 hours) post-dose

Interventionng*hr/mL (Geometric Mean)
Part 1: Soticlestat 300 mg Alone1391
Part 1: Soticlestat 300 mg + Itraconazole 200 mg1697

[back to top]

Part 1, Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Itraconazole

(NCT05064449)
Timeframe: Soticlestat alone: Period 1, Day 1 pre-dose and at multiple timepoints (up to 96 hours) post-dose; Soticlestat with itraconazole: Period 2, Day 5 pre-dose and at multiple timepoints (up to 168 hours) post-dose

Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
Part 1: Soticlestat 300 mg Alone1310
Part 1: Soticlestat 300 mg + Itraconazole 200 mg1527

[back to top]

Part 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Soticlestat When Administered Alone and With Itraconazole

(NCT05064449)
Timeframe: Soticlestat alone: Period 1, Day 1 pre-dose and at multiple timepoints (up to 96 hours) post-dose; Soticlestat with itraconazole: Period 2, Day 5 pre-dose and at multiple timepoints (up to 168 hours) post-dose

Interventionhour (Median)
Part 1: Soticlestat 300 mg Alone0.500
Part 1: Soticlestat 300 mg + Itraconazole 200 mg0.503

[back to top]

Part 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Soticlestat When Administered Alone and With Mefenamic Acid

(NCT05064449)
Timeframe: Soticlestat alone: Period 1, Day 1 pre-dose and at multiple timepoints (up to 96 hours) post-dose; Soticlestat with mefenamic acid: Period 2, Day 2 pre-dose and at multiple timepoints (up to 144 hours) post-dose

Interventionng*hr/mL (Geometric Mean)
Part 2: Soticlestat 300 mg Alone1533
Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg and 250 mg1594

[back to top]

Part 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat When Administered Alone and With Mefenamic Acid

(NCT05064449)
Timeframe: Soticlestat alone: Period 1, Day 1 pre-dose and at multiple timepoints (up to 96 hours) post-dose; Soticlestat with mefenamic acid: Period 2, Day 2 pre-dose and at multiple timepoints (up to 144 hours) post-dose

Interventionng*hr/mL (Geometric Mean)
Part 2: Soticlestat 300 mg Alone1423
Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg and 250 mg1528

[back to top]

Part 2, Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Mefenamic Acid

(NCT05064449)
Timeframe: Soticlestat alone: Period 1, Day 1 pre-dose and at multiple timepoints (up to 96 hours) post-dose; Soticlestat with mefenamic acid: Period 2, Day 2 pre-dose and at multiple timepoints (up to 144 hours) post-dose

Interventionng/mL (Geometric Mean)
Part 2: Soticlestat 300 mg Alone1414
Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg and 250 mg1517

[back to top]

Part 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Soticlestat When Administered Alone and With Mefenamic Acid

(NCT05064449)
Timeframe: Soticlestat alone: Period 1, Day 1 pre-dose and at multiple timepoints (up to 96 hours) post-dose; Soticlestat with mefenamic acid: Period 2, Day 2 pre-dose and at multiple timepoints (up to 144 hours) post-dose

Interventionhour (Median)
Part 2: Soticlestat 300 mg Alone0.505
Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg and 250 mg0.522

[back to top]

Parts 1 and 2: Number of Participants Reported One or More Treatment-emergent Adverse Event (TEAE)

(NCT05064449)
Timeframe: Part 1: from Day 1 of Period 1 up to 15 days after the last dose of soticlestat in Period 2 (up to Day 20 in Period 2); Part 2: from Day 1 of Period 1 up to 15 days after the last dose of soticlestat in Period 2 (up to Day 17 in Period 2)

InterventionParticipants (Count of Participants)
Part 1: Soticlestat 300 mg Alone1
Part 1: Itraconazole 200 mg Alone2
Part 1: Soticlestat 300 mg + Itraconazole 200 mg3
Part 2: Soticlestat 300 mg Alone1
Part 2: Mefenamic Acid 500 mg and 250 mg0
Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg and 250 mg3

[back to top]

Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Electrocardiogram (ECG)

(NCT05064449)
Timeframe: Part 1: Day 1 of Period 1 up to Day 12 of Period 2; Part 2: Day 1 of Period 1 up to Day 8 of Period 2

InterventionParticipants (Count of Participants)
Part 1: Soticlestat 300 mg Alone0
Part 1: Itraconazole 200 mg Alone0
Part 1: Soticlestat 300 mg + Itraconazole 200 mg0
Part 2: Soticlestat 300 mg Alone0
Part 2: Mefenamic Acid 500 mg and 250 mg0
Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg and 250 mg0

[back to top]

Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Laboratory Evaluations

(NCT05064449)
Timeframe: Part 1: Day 1 of Period 1 up to Day 12 of Period 2; Part 2: Day 1 of Period 1 up to Day 8 of Period 2

InterventionParticipants (Count of Participants)
Part 1: Soticlestat 300 mg Alone0
Part 1: Itraconazole 200 mg Alone0
Part 1: Soticlestat 300 mg + Itraconazole 200 mg0
Part 2: Soticlestat 300 mg Alone0
Part 2: Mefenamic Acid 500 mg and 250 mg0
Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg and 250 mg0

[back to top]

Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Vital Signs

(NCT05064449)
Timeframe: Part 1: Day 1 of Period 1 up to Day 12 of Period 2; Part 2: Day 1 of Period 1 up to Day 8 of Period 2

InterventionParticipants (Count of Participants)
Part 1: Soticlestat 300 mg Alone0
Part 1: Itraconazole 200 mg Alone0
Part 1: Soticlestat 300 mg + Itraconazole 200 mg0
Part 2: Soticlestat 300 mg Alone0
Part 2: Mefenamic Acid 500 mg and 250 mg0
Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg and 250 mg0

[back to top]

Parts 1 and 2: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)

"The C-SSRS is an interview-based rating scale to systematically assess any suicidality, suicidal behavior, or suicidal ideation. Any suicidality is emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior was indicated when response was yes for any these questions- actual attempted to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation was indicated when response was yes for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intended to act, without specific plan or with specific plan and intended to suicide." (NCT05064449)
Timeframe: Part 1: Day 1 of Period 1 up to Day 12 of Period 2; Part 2: Day 1 of Period 1 up to Day 8 of Period 2

InterventionParticipants (Count of Participants)
Part 1: Soticlestat 300 mg Alone0
Part 1: Itraconazole 200 mg Alone0
Part 1: Soticlestat 300 mg + Itraconazole 200 mg0
Part 2: Soticlestat 300 mg Alone0
Part 2: Mefenamic Acid 500 mg and 250 mg0
Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg and 250 mg0

[back to top]